Profile of Dr Kathryn Chapman
Kathryn Chapman is the Deputy Director of the Milner Therapeutics Institute at the University of Cambridge. The Milner Therapeutics Institute is a new University research institute which opened in late 2019 in the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, providing a physical hub for translational science and collaboration between industry and academia. The Institute is a centre of excellence for target validation through artificial intelligence, machine-learning, functional genomics and tool compound analyses.
Kathryn has a biomedical research background and has previously carried out target discovery research in multiple disease areas at the University of Manchester, Harvard Medical School, Wellcome Sanger Institute and GlaxoSmithKline. Prior to joining the Milner Therapeutics Institute in February 2016, Kathryn spent 10 years working at the NC3Rs with 40+ pharmaceutical companies in the US and Europe to improve scientific and business processes in drug development. While at the NC3Rs, Kathryn founded and directed a new challenge-led open innovation platform, CRACK IT which increases cross-discipline and cross-sector industry/academic partnerships in applied research. Kathryn has 50+ research publications and has been on a wide-range of national and international review panels (Innovate UK, Innovative Medicines Initiative and BBSRC). She holds an honorary professorship at the University of Coventry where she sits on the Vice Chancellor’s advisory group.